Med­i­ci­No­va flops in PhII metham­phet­a­mine de­pen­dence tri­al, stock slips

San Diego drug­mak­er Med­i­ci­No­va has flunked a mid-stage tri­al test­ing its lead drug can­di­date against metham­phet­a­mine de­pen­dence, send­ing the com­pa­ny’s stock quick­ly south in pre-mar­ket trad­ing.

The com­pa­ny an­nounced Thurs­day that its Phase II clin­i­cal tri­al as­sess­ing MN-166, a drug called ibudi­last, failed to achieve the study’s pri­ma­ry end­point: metham­phet­a­mine ab­sti­nence dur­ing the last weeks of treat­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER